Several studies demonstrated that O-GlcNAc mitigates neurodegeneration (Yuzwa et al., 2012; Hastings et al., 2017; Park et al., 2021); therefore, we hypothesize that the elevation of ATF4 in AD is associated with disruptions in O-GlcNAcylation. Here, ATF4 is linked to Alzheimer disease.